Current stock page

Catalysts

ZYME Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

ZYMEZymeworks Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$26.24−$0.23 (−0.87%)

Latest quote

  • Momentum
    78
  • Value
    66
  • Quality
    62
  • Risk resilience
    61
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 1, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 68/100

Momentum 78/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 11.43%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 78/100AIQ Edge 8/10 Strong Relative Position
Beat rate
50%
4 of 8 reported periods
Average surprise
-450.3%
Across covered historical reports
Latest result
+0.4%
Nov 9, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 9, 2026—$2.27$2.28+0.4%$227.4M$256.46M
Aug 6, 2026—-$0.57-$0.62-7.9%$4.54M$4.59M
May 7, 2026—-$0.10-$0.59-490.0%$24.38M$2.41M
Mar 2, 2026—-$0.35-$0.55-57.1%$19.24M$2.52M
Nov 6, 2025—-$0.30-$0.26+13.3%$19.49M$27.61M
Aug 7, 2025—-$0.52$0.03+105.8%$25.75M$48.73M
May 8, 2025—-$0.45-$0.30+33.3%$18.02M$27.11M
Mar 5, 2025—$0.01-$0.31-3200.0%$15.2M$31.03M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
14
Buy
12-month analyst target
$42.60
+62.35% versus current price
Based on 14 analyst observations. Targets are estimates, not predictions.
Low target
$32.00
+21.95% vs latest price
Average target
$42.60
+62.35% vs latest price
High target
$55.00
+109.60% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 1, 2027

Next known earnings or reporting date.

EPS estimate$0.11

Current analyst expectation for the upcoming report.

Revenue estimate$72.52M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score78

Where event reaction would show up first.

AIQ score68/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
14
Average target
$42.60
Target upside
62.35%
Target range
$32.00 - $55.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
2
Negative
1
zacks.com · Nov 9, 2026

Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of -5.00% and +2.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

seekingalpha.com · Oct 29, 2026

Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates - Slideshow (NASDAQ:ZYME) 2026-10-29

2026-10-29. The following slide deck was published by Zymeworks Inc.

gurufocus.com · Oct 28, 2026

ZYME Maintained by Truist Securities -- Price Target Raised to $35

Zymeworks Inc. Analyst Rating Update On October 6, 2023, Truist Securities maintained a Buy rating for Zymeworks (ZYME) while raising the price target to $35

gurufocus.com · Oct 24, 2026

Zymeworks (ZYME) Reports Strong Phase 1 Results for ZW191 in Ovarian Cancer

On October 24, 2026, Zymeworks Inc. (NASDAQ: ZYME) announced promising Phase 1 clinical trial outcomes for its antibody-drug conjugate ZW191, targeting folate r

seekingalpha.com · Sep 28, 2026

Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Inc. (ZYME) M&A Call September 28, 2026 8:30 AM EDTCompany ParticipantsShrinal Inamdar - Vice President of Investor RelationsScott Platshon -...

Open full news and sentiment

ZYME Catalysts FAQ

What are the next catalysts for ZYME stock?

ZYME's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ZYME stock?

Upcoming events that could move ZYME include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ZYME's next earnings report affect the stock?

ZYME's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ZYME stock higher?

ZYME could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ZYME stock?

ZYME could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.